RESUMEN
INTRODUCTION: Aspartame, invented in 1965 by GD-Searle, is an intense artificial sweetener taste approximately 200 times as sweet as sucrose and used as an additive in more than 6,000 products. Aspartame (APM) was submitted for pre-marketing safety evaluation in early 1980. The studies, performed by GD-Searle, produced controversial results. AREAS COVERED: Because of the great commercial diffusion of aspartame, in 1997 the Ramazzini Institute (RI) started a large experimental project on rodents to test the carcinogenic effects of aspartame following an experimental model with more sensitive characteristics, namely a large number of rat and mice, starting treatment from prenatal life, observation until spontaneous death. Overall, the project included studying 2270 rats and 852 mice. These studies have shown that aspartame is a carcinogenic agent in experimental animals, inducing a significant dose-related increased incidence of several types of malignant tumors and, among them, hematological neoplasia, and liver cancer. EXPERT OPINION: The results of these studies on aspartame by the Ramazzini Institute opened a real front on the evaluation of artificial sweeteners and their possible health risks. Adequate long-term carcinogenicity bioassays on other diffuse artificial sweeteners such as acesulfame-k, sucralose, saccharin, including their blends, are likewise important for public health.
Asunto(s)
Aspartame , Carcinógenos , Relación Dosis-Respuesta a Droga , Neoplasias , Edulcorantes , Aspartame/efectos adversos , Aspartame/administración & dosificación , Animales , Edulcorantes/efectos adversos , Edulcorantes/administración & dosificación , Edulcorantes/farmacología , Ratones , Neoplasias/inducido químicamente , Neoplasias/patología , Ratas , Humanos , Carcinógenos/toxicidad , Carcinógenos/administración & dosificación , Pruebas de CarcinogenicidadRESUMEN
AIM: To evaluate whether caffeine combined with a moderate amount of glucose reduces the risk for exercise-related hypoglycaemia compared with glucose alone or control in adult people with type 1 diabetes using ultra-long-acting insulin degludec. MATERIALS AND METHODS: Sixteen participants conducted three aerobic exercise sessions (maximum 75 min) in a randomized, double-blind, cross-over design. Thirty minutes before exercise, participants ingested a drink containing either 250 mg of caffeine + 10 g of glucose + aspartame (CAF), 10 g of glucose + aspartame (GLU), or aspartame alone (ASP). The primary outcome was time to hypoglycaemia. RESULTS: There was a significant effect of the condition on time to hypoglycaemia (χ2 = 7.674, p = .0216). Pairwise comparisons revealed an 85.7% risk reduction of hypoglycaemia for CAF compared with ASP (p = .044). No difference was observed between GLU and ASP (p = .104) or between CAF and GLU (p = .77). While CAF increased glucose levels during exercise compared with GLU and ASP (8.3 ± 1.9 mmol/L vs. 7.7 ± 2.2 mmol/L vs. 5.8 ± 1.4 mmol/L; p < .001), peak plasma glucose levels during exercise did not differ between CAF and GLU (9.3 ± 1.4 mmol/L and 9.1 ± 1.6 mmol/L, p = .80), but were higher than in ASP (6.6 ± 1.1 mmol/L; p < .001). The difference in glucose levels between CAF and GLU was largest during the last 15 min of exercise (p = .002). Compared with GLU, CAF lowered perceived exertion (p = .023). CONCLUSIONS: Pre-exercise caffeine ingestion combined with a low dose of glucose reduced exercise-related hypoglycaemia compared with control while avoiding hyperglycaemia.
Asunto(s)
Glucemia , Cafeína , Estudios Cruzados , Diabetes Mellitus Tipo 1 , Ejercicio Físico , Hipoglucemia , Insulina de Acción Prolongada , Humanos , Insulina de Acción Prolongada/administración & dosificación , Insulina de Acción Prolongada/uso terapéutico , Método Doble Ciego , Diabetes Mellitus Tipo 1/tratamiento farmacológico , Diabetes Mellitus Tipo 1/sangre , Diabetes Mellitus Tipo 1/complicaciones , Masculino , Femenino , Cafeína/administración & dosificación , Adulto , Hipoglucemia/prevención & control , Hipoglucemia/inducido químicamente , Glucemia/metabolismo , Glucemia/efectos de los fármacos , Hipoglucemiantes/uso terapéutico , Hipoglucemiantes/administración & dosificación , Glucosa/metabolismo , Persona de Mediana Edad , Aspartame/administración & dosificación , Aspartame/efectos adversosRESUMEN
To cover the unpleasant taste of amoxicillin (250 mg), maize starch (baby food) and milk chocolate were co-formulated. The raw materials and the final formulations were characterized by means of Dynamic Light Scattering (DLS), Differential Scanning Calorimetry (DSC) and Fourier-Transform Infrared (FT-IR) spectroscopy. To evaluate the taste masking two different groups of volunteers were used, according to the Ethical Research Committee of the Aristotle University of Thessaloniki. The optimization of excipients' content in the tablet was determined by experimental design methodology (crossed D-optimal). Due to the matrix complexity, amoxicillin was extracted using liquid extraction and analyzed isocratically by HPLC. The developed chromatographic method was validated (%Recovery 98.7-101.3, %RSD = 1.3, LOD and LOQ 0.15 and 0.45 µg mL-1 respectively) according to the International Conference on Harmonization (ICH) guidelines. The physicochemical properties of the tablets were also examined demonstrating satisfactory quality characteristics (diameter: 15 mm, thickness: 6 mm, hardness <98 Newton, loss of mass <1.0%, disintegration time â¼25min). Additionally, dissolution (%Recovery >90) and in vitro digestion tests (%Recovery >95) were carried out. Stability experiments indicated that amoxicillin is stable in the prepared formulations for at least one year (%Recovery <91).
Asunto(s)
Amoxicilina/síntesis química , Antibacterianos/síntesis química , Química Farmacéutica/métodos , Composición de Medicamentos/métodos , Desarrollo de Medicamentos/métodos , Gusto/efectos de los fármacos , Administración Oral , Adolescente , Adulto , Amoxicilina/administración & dosificación , Amoxicilina/farmacocinética , Antibacterianos/administración & dosificación , Antibacterianos/farmacocinética , Aspartame/administración & dosificación , Aspartame/síntesis química , Aspartame/farmacocinética , Niño , Chocolate , Evaluación Preclínica de Medicamentos/métodos , Excipientes/administración & dosificación , Excipientes/síntesis química , Excipientes/farmacocinética , Femenino , Humanos , Masculino , Masticación/efectos de los fármacos , Masticación/fisiología , Comprimidos , Gusto/fisiología , Adulto Joven , Zea maysRESUMEN
Artificial sweeteners (AS) are synthetic sugar substitutes that are commonly consumed in the diet. Recent studies have indicated considerable health risks which links the consumption of AS with metabolic derangements and gut microbiota perturbations. Despite these studies, there is still limited data on how AS impacts the commensal microbiota to cause pathogenicity. The present study sought to investigate the role of commonly consumed AS on gut bacterial pathogenicity and gut epithelium-microbiota interactions, using models of microbiota (Escherichia coli NCTC10418 and Enterococcus faecalis ATCC19433) and the intestinal epithelium (Caco-2 cells). Model gut bacteria were exposed to different concentrations of the AS saccharin, sucralose, and aspartame, and their pathogenicity and changes in interactions with Caco-2 cells were measured using in vitro studies. Findings show that sweeteners differentially increase the ability of bacteria to form a biofilm. Co-culture with human intestinal epithelial cells shows an increase in the ability of model gut bacteria to adhere to, invade and kill the host epithelium. The pan-sweet taste inhibitor, zinc sulphate, effectively blocked these negative impacts. Since AS consumption in the diet continues to increase, understanding how this food additive affects gut microbiota and how these damaging effects can be ameliorated is vital.
Asunto(s)
Enterococcus faecalis/efectos de los fármacos , Escherichia coli/efectos de los fármacos , Microbioma Gastrointestinal/efectos de los fármacos , Edulcorantes/farmacología , Aspartame/administración & dosificación , Aspartame/farmacología , Adhesión Bacteriana/efectos de los fármacos , Biopelículas/efectos de los fármacos , Células CACO-2 , Relación Dosis-Respuesta a Droga , Enterococcus faecalis/patogenicidad , Escherichia coli/patogenicidad , Microbioma Gastrointestinal/fisiología , Hemólisis/efectos de los fármacos , Humanos , Sacarina/administración & dosificación , Sacarina/farmacología , Sacarosa/administración & dosificación , Sacarosa/análogos & derivados , Sacarosa/farmacología , Edulcorantes/administración & dosificaciónRESUMEN
Aspartame is one of the most common consumed artificial sweeteners utilized in many food products and beverages. It has been indicated that long-term consumption of aspartame leads to reproductive toxicity but its mechanism is not well-clear. In this study we investigated mechanism of aspartame-induced reproductive toxicity in male mice. For this purpose, 36 NMRI mature male mice received three doses of 40, 80, and 160 mg/kg body weight of aspartame, respectively per day by gavage for 90 days and also a control group was considered which received 0.5 mL of normal saline as the same route. The results revealed that long-term administration of aspartame at high doses significantly (P < .05) reduced gonadosomatic index, serum concentration of pituitary-testicular axis hormones (FSH, LH, and testosterone). It also decreased sperm parameters and total antioxidant capacity, antioxidant enzyme activities (superoxide dismutase, catalase, and glutathione peroxidase), while it caused increase in nitric oxide and malondialdehyde levels in testis tissue and sperm samples. Also, it decreased attenuated testicular histomorphometric indices (tubular differentiation index, spermiogenesis index, and repopulation index), and steroidogenic foci, while increased mRNA damages and apoptosis rate, downregulated antiapoptotic (Bcl-2) and upregulated proapoptotic (P53, BAX, and caspase-3) mediators respectively in testis. These findings indicated that consumption of aspartame for a long period results in male reproductive toxicity by decrease in serum concentration of pituitary-testis axis hormones and induction of oxidative stress and apoptosis in testis.
Asunto(s)
Antioxidantes/metabolismo , Apoptosis/efectos de los fármacos , Aspartame/toxicidad , Estrés Oxidativo/efectos de los fármacos , Testículo/efectos de los fármacos , Animales , Aspartame/administración & dosificación , Proteínas Relacionadas con la Autofagia/metabolismo , Caspasas/metabolismo , Relación Dosis-Respuesta a Droga , Glutatión Peroxidasa/metabolismo , Masculino , Malondialdehído/metabolismo , Ratones , Espermatogénesis/efectos de los fármacos , Superóxido Dismutasa/metabolismo , Testículo/metabolismo , Testosterona/sangreRESUMEN
The breakdown of the intestinal epithelial barrier and subsequent increase in intestinal permeability can lead to systemic inflammatory diseases and multiple-organ failure. Nutrition impacts the intestinal barrier, with dietary components such as gluten increasing permeability. Artificial sweeteners are increasingly consumed by the general public in a range of foods and drinks. The sweet taste receptor (T1R3) is activated by artificial sweeteners and has been identified in the intestine to play a role in incretin release and glucose transport; however, T1R3 has not been previously linked to intestinal permeability. Here, the intestinal epithelial cell line, Caco-2, was used to study the effect of commonly-consumed artificial sweeteners, sucralose, aspartame and saccharin, on permeability. At high concentrations, aspartame and saccharin were found to induce apoptosis and cell death in intestinal epithelial cells, while at low concentrations, sucralose and aspartame increased epithelial barrier permeability and down-regulated claudin 3 at the cell surface. T1R3 knockdown was found to attenuate these effects of artificial sweeteners. Aspartame induced reactive oxygen species (ROS) production to cause permeability and claudin 3 internalization, while sweetener-induced permeability and oxidative stress was rescued by the overexpression of claudin 3. Taken together, our findings demonstrate that the artificial sweeteners sucralose, aspartame, and saccharin exert a range of negative effects on the intestinal epithelium through the sweet taste receptor T1R3.
Asunto(s)
Mucosa Intestinal/efectos de los fármacos , Receptores Acoplados a Proteínas G/efectos de los fármacos , Edulcorantes/farmacología , Uniones Estrechas/efectos de los fármacos , Animales , Apoptosis/efectos de los fármacos , Aspartame/administración & dosificación , Células CACO-2 , Claudina-3/genética , Claudinas/genética , Expresión Génica/efectos de los fármacos , Técnicas de Silenciamiento del Gen , Humanos , Mucosa Intestinal/fisiología , Masculino , Ratones , Ratones Endogámicos C57BL , Estrés Oxidativo/efectos de los fármacos , Permeabilidad/efectos de los fármacos , Receptores Acoplados a Proteínas G/genética , Receptores Acoplados a Proteínas G/fisiología , Sacarosa/administración & dosificación , Sacarosa/análogos & derivados , Edulcorantes/administración & dosificación , Uniones Estrechas/fisiologíaRESUMEN
The objective of this study was to test the hypothesis that aspartame supplementation in starter diet accelerates small intestinal cell cycle by stimulating secretion and expression of glucagon-like peptide -2 (GLP-2) in pre-weaned lambs using animal and cell culture experiments. In vivo, twelve 14-day-old lambs were selected and allocated randomly to two groups; one was treated with plain starter diet (Con, n = 6) and the other was treated with starter supplemented with 200 mg of aspartame/kg starter (APM, n = 6). Results showed that the lambs received APM treatment for 35 d had higher (p < .05) GLP-2 concentration in the plasma and greater jejunum weight/live body weight (BW) and jejunal crypt depth. Furthermore, APM treatment significantly upregulated (p < .05) the mRNA expression of cyclin D1 in duodenum; and cyclin A2, cyclin D1, cyclin-dependent kinases 6 (CDK6) in jejunum; and cyclin A2, cyclin D1, CDK4 in ileum. Moreover, APM treatment increased (p < .05) the mRNA expression of glucagon (GCG), insulin-like growth factor 1 (IGF-1) in the jejunum and ileum and mRNA expression of GLP-2 receptor (GLP-2R) in the jejunum. In vitro, when jejunal cells were treated with GLP-2 for 2 hr, the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) OD, IGF-1 concentration, and the mRNA expression of IGF-1, cyclin D1 and CDK6 were increased (p < .05). Furthermore, IGF-1 receptor (IGF-1R) inhibitor decreased (p < .05) the mRNA expression of IGF-1, cyclin A2, cyclin D1 and CDK6 in GLP-2 treatment jejunal cells. These results suggest that aspartame supplementation in starter accelerates small intestinal cell cycle that may, in part, be related to stimulate secretion and expression of GLP-2 in pre-weaning lambs. Furthermore, GLP-2 can indirectly promote the proliferation of jejunal cells mainly through the IGF-1 pathway. These findings provide new insights into nutritional interventions that promote the development of small intestines in young ruminants.
Asunto(s)
Aspartame/farmacología , Células Epiteliales/efectos de los fármacos , Péptido 2 Similar al Glucagón/metabolismo , Mucosa Intestinal/citología , Intestino Delgado/efectos de los fármacos , Ovinos/fisiología , Alimentación Animal , Animales , Animales Lactantes , Aspartame/administración & dosificación , Células Cultivadas , Células Epiteliales/fisiología , Regulación de la Expresión Génica/efectos de los fármacos , Péptido 2 Similar al Glucagón/genética , Receptor del Péptido 2 Similar al Glucagón/genética , Receptor del Péptido 2 Similar al Glucagón/metabolismo , Factor I del Crecimiento Similar a la Insulina/genética , Factor I del Crecimiento Similar a la Insulina/metabolismo , Mucosa Intestinal/efectos de los fármacos , Proglucagón/genética , Proglucagón/metabolismo , ARN Mensajero/genética , ARN Mensajero/metabolismo , Receptor IGF Tipo 1/genética , Receptor IGF Tipo 1/metabolismoRESUMEN
INTRODUCTION: Introduction: consumption of non-caloric sweeteners (NCS) has increased worldwide in the last 35 years. Objective: to determine the consumption of NCS among pregnant Chilean women and measure if consumption exceeded the acceptable daily intake. Methods: we conducted a cross-sectional study of pregnant women from the two main cities in Chile. Women were interviewed to determine the consumption of NCS and socioeconomic level; anthropometry was measured. Results: six hundred and one pregnant women were interviewed; 98% of pregnant women surveyed consumed NCS. The most consumed sweetener was sucralose (95.6%), followed by acesulfame k (80.6%), stevia (78.3%), aspartame (75.1%), saccharin (14.8%), and cyclamate (10%). We observed that consumption closest to the acceptable daily intake was reported for stevia (82.5%), followed by acesulfame k (44%). However, except stevia, which reached 12%, average values were under 5% of the acceptable daily intake. No pregnant woman in the sample exceeded the acceptable daily intake and there were no differences in sweetener consumption by trimester of pregnancy or by socioeconomic level. Conclusions: a high prevalence of NCS consumption was observed, however, none of the pregnant women exceeded the acceptable daily intake.
INTRODUCCIÓN: Introducción: el consumo de edulcorantes no calóricos (ENC) ha aumentado en todo el mundo en los últimos 35 años. Objetivo: determinar el consumo de ENC en embarazadas chilenas y medir si el consumo excede la ingesta diaria admisible (IDA). Métodos: realizamos un estudio transversal en embarazadas, proveniente de las dos principales ciudades de Chile. Se las entrevistó para determinar el consumo de ENC y nivel socioeconómico, además se realizó antropometría. Resultados: se entrevistaron a 601 embarazadas; el 98% de las embarazadas encuestadas consumieron ENC. El edulcorante más consumido fue sucralosa (95,6%), seguido de acesulfamo k (80,6%), estevia (78,3%), aspartamo (75,1%), sacarina (14,8%) y ciclamato (10%). Observamos que el consumo más cercano a la IDA se reportó para la estevia (82,5%), seguido de acesulfamo k (44%). Sin embargo, excepto la estevia, que alcanzó el 12% de adecuación con respecto al IDA, los valores promedio estuvieron por debajo del 5% de la IDA. Ninguna mujer embarazada en la muestra excedió la IDA y no hubo diferencias en el consumo de ENC por trimestre del embarazo o por nivel socioeconómico. Conclusiones: se observó una alta prevalencia de consumo de ENC, sin embargo, ninguna de las mujeres embarazadas excedió la IDA.
Asunto(s)
Edulcorantes no Nutritivos/administración & dosificación , Ingesta Diaria Recomendada , Adulto , Aspartame/administración & dosificación , Chile , Estudios Transversales , Ciclamatos/administración & dosificación , Diterpenos de Tipo Kaurano/administración & dosificación , Femenino , Glucósidos/administración & dosificación , Humanos , Embarazo , Mujeres Embarazadas , Sacarina/administración & dosificación , Clase Social , Sacarosa/administración & dosificación , Sacarosa/análogos & derivados , Tiazinas/administración & dosificaciónRESUMEN
Background Aspartame (ASP) is used for treatment of obesity and diabetes mellitus. This study was designed to illustrate the biochemical responses and histopathological alterations besides the genotoxicity of ASP alone or with l-carnitine (LC) in the liver of rats. Methods Animals were separated into six groups: control, lower dose of ASP (ASP-LD; 75 mg/kg), higher dose of ASP (ASP-HD; 150 mg/kg), l-carnitine (LC; 10 mg/kg), ASP-LD plus LC, and ASP-HD plus LC. Treatment was carried out orally for 30 consecutive days. Results ASP raised the activity of some enzymes of liver markers and disturbed the lipid profile levels. The hepatic reduced glutathione (GSH) levels, the marker enzymes of antioxidant activities, were obviously diminished, and, possibly, the lipid peroxidation, C-reactive protein, and interleukins levels were increased. ASP significantly increased the DNA deterioration in comparison with the control in a dose-dependent manner. LC prevented ASP-induced liver damage as demonstrated by the enhancement of all the above parameters. Results of histopathological and electron microscopic examination proved the biochemical feedback and the improved LC effect on liver toxicity. Conclusions The co-treatment of LC showed different improvement mechanisms against ASP-induced liver impairment. So, the intake of ASP should be regulated and taken with LC when it is consumed in different foods or drinks to decrease its oxidative stress, histopathology, and genotoxicity of liver.
Asunto(s)
Aspartame/toxicidad , Carnitina/farmacología , Hígado/efectos de los fármacos , Estrés Oxidativo/efectos de los fármacos , Animales , Antioxidantes/metabolismo , Aspartame/administración & dosificación , Proteína C-Reactiva/metabolismo , Relación Dosis-Respuesta a Droga , Glutatión/metabolismo , Interleucinas/metabolismo , Metabolismo de los Lípidos/efectos de los fármacos , Peroxidación de Lípido/efectos de los fármacos , Hígado/patología , Masculino , Microscopía Electrónica/métodos , Pruebas de Mutagenicidad , RatasRESUMEN
Two studies were conducted to further assess its mutagenic and genotoxic potential. In a bacterial reverse mutation pre-incubation study, Salmonella typhimurium strains TA100, TA1535, TA98, and TA1537 and Escherichia coli WP2 uvrA were treated with aspartame at concentrations of up to 5000 µg/plate with or without metabolic activation and showed no mutagenic potential. Similarly, in vivo micronucleus testing of aspartame following gavage administration (500-2000â¯mg/kg body weight) to Crlj:CD1(ICR) strain SPF male mice showed no increase in the proportion of micronucleated polychromatic erythrocytes in bone marrow cells collected and evaluated 24 or 48â¯h post administration. Overall, aspartame had no potential for mutagenic or genotoxic activity.
Asunto(s)
Aspartame/toxicidad , Mutágenos/toxicidad , Edulcorantes/toxicidad , Administración Oral , Animales , Aspartame/administración & dosificación , Humanos , Ratones , Ratones Endogámicos ICR , Pruebas de Mutagenicidad , Mutágenos/administración & dosificación , Edulcorantes/administración & dosificaciónRESUMEN
The current review assessed cancer studies of aspartame based on a quality appraisal using the Klimisch grading system. Nine studies having complete histopathology were included: three 2-year studies by Searle; three transgenic mice studies by the NTP; three lifetime studies by the Ramazzini Institute. A tenth study limited to brain tumors was not rated. None were determined as Klimisch Code 1 (reliable without restrictions). The Searle studies predated GLP standards but their methodology was comparable; transgenic mouse models are not validated, but are accepted as supporting data. These studies were rated Klimisch Code 2 (reliable with restrictions). The Ramazzini Institute used a lifetime model of their own design that has been questioned due to high rates of spontaneous tumors, issues with tumor type diagnosis and concerns about the impact of chronic infections. As many of these problems could be attributed to using animals that died or were terminated near end of life, along with the other problems noted, these studies were rated Klimisch Code 3 (not reliable). As the Klimisch Code 2 studies demonstrated a lack of carcinogenic potential, and as aspartame is hydrolyzed to common components and lacks genotoxic activity, a conclusion that aspartame is not carcinogenic is supported.
Asunto(s)
Aspartame/análisis , Edulcorantes/análisis , Animales , Aspartame/administración & dosificación , Pruebas de Carcinogenicidad , Ratones , Ratones Transgénicos , Edulcorantes/administración & dosificaciónRESUMEN
Aspartame (NutraSweet®, Equal®) is a widely used artificial sweetener, has been reported to be accountable for neurological and behavioural disturbances in people. Upon ingestion, aspartame is hydrolyzed in gut and provides its metabolite; such as essential amino acid phenylalanine (Phy) (50%), aspartic acid (40%), and methanol (10%). Altered brain neurochemical compositions [such as dopamine (DA), norepinephrine (NE), and serotonin (5-HT)] have long been a concern and being involved in observed neurophysiological symptom (such as headaches, memory loss, mood changes, as well as depression) in aspartame consumers. Aspartames might act as chemical stressor through increasing plasma cortisol level. Aspartame consumption similarly altered gut microbiota. Taken together all this factors, we reviewed to search for convincing evidence, in what manner aspartame metabolites, stress hormones (cortisol), and gut dysbiosisis involved in altering brain neurochemical composition. We concluded that aspartame metabolite; mainly Phy and its interaction with neurotransmitter and aspartic acid by acting as excitatory neurotransmitter causes this pattern of impairments. Along with elevated cortisol and gut dysbiosis via interactions with different biogenic amine may also have additional impact to modulate neuronal signaling lead to neurobiological impairments. Hence ongoing research is instantly needed to understand the specific roles of aspartame metabolite, elevated cortisol, and gut dysbiosis with emerging neurophysiological symptom in aspartame consumers to improve healthy life in its consumers.
Asunto(s)
Aspartame/administración & dosificación , Aspartame/metabolismo , Neurotransmisores/metabolismo , Edulcorantes/administración & dosificación , Edulcorantes/metabolismo , Animales , Aspartame/efectos adversos , Ácido Aspártico/metabolismo , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Disbiosis/inducido químicamente , Disbiosis/metabolismo , Humanos , Hidrocortisona/metabolismo , Norepinefrina/metabolismo , Fenilalanina/metabolismo , Edulcorantes/efectos adversosRESUMEN
Aspartame, an artificial sweetening agent belongs to dipeptide chemical category with a very strong sweetening potential. Although research findings in humans and non-human primates have demonstrated numerous negative effects of aspartame (biochemical, histological, neurological, behavioral, genetic etc)., the status of aspartame is still debatable. Present manuscript is a critical review of the substantial research findings related to aspartame intake on different research models. Purpose of this review was to spread the awareness about adverse effect of aspartame intake to outline the occurrence of health issues among the population. The process of uptake, storage, compartmentalization and distribution of aspartame within the body is associated with metabolic disorders and various clinical conditions. Available research literature indicates that higher amount of aspartame ingestion should be monitored carefully to avoid health implication within society.
Asunto(s)
Aspartame/administración & dosificación , Aspartame/efectos adversos , Animales , Ingestión de Alimentos/fisiología , Humanos , Edulcorantes/administración & dosificación , Edulcorantes/efectos adversosRESUMEN
Artificial sweeteners are mainly used as substitutes for sucrose derivates. In this study, we analyzed if the chronic consumption of aspartame or acesulfame potassium at an early age, produces histological alterations, astrogliosis and decreased neuronal viability, in hippocampus, prefrontal cortex, amygdala and hypothalamus of male Wistar rats. A histological analysis was performed on male Wistar rats that consumed aspartame or acesulfame potassium during 90 days, initiating the consumption of sweeteners immediately after weaning. The evaluation of neuronal morphology in different areas of the brain was performed with hematoxylin - eosin staining. To measure astrogliosis and neuronal viability, we used the immunohistochemical technique, with the glial fibrillary acidic protein immunomodulators (GFAP) and with neuronal-specific enolase (NSE). The consumption of aspartame or acesulfame potassium promoted morphological changes of neurons including increased pyknotic nuclei and vacuolization in all the brain areas studied. In hippocampus, prefrontal cortex, amygdala and hypothalamus, astrogliosis and reduction of neural viability were observed in sweeteners consumers in comparison with the control group. Chronic consumption of ASP and ACK from early stages of development and during long periods, may promote neural modifications, astrogliosis and decrease neuronal viability in prefrontal cortex, amygdala, hippocampus, and hypothalamus.
Asunto(s)
Aspartame/toxicidad , Encéfalo/efectos de los fármacos , Gliosis/inducido químicamente , Neuronas/efectos de los fármacos , Edulcorantes/toxicidad , Tiazinas/toxicidad , Animales , Aspartame/administración & dosificación , Encéfalo/patología , Supervivencia Celular/efectos de los fármacos , Supervivencia Celular/fisiología , Gliosis/patología , Masculino , Neuronas/patología , Ratas , Ratas Wistar , Edulcorantes/administración & dosificación , Tiazinas/administración & dosificaciónRESUMEN
Aspartame (α-aspartyl-l-phenylalanine-o-methyl ester), an artificial sweetener, has been linked to behavioral and cognitive problems. Possible neurophysiological symptoms include learning problems, headache, seizure, migraines, irritable moods, anxiety, depression, and insomnia. The consumption of aspartame, unlike dietary protein, can elevate the levels of phenylalanine and aspartic acid in the brain. These compounds can inhibit the synthesis and release of neurotransmitters, dopamine, norepinephrine, and serotonin, which are known regulators of neurophysiological activity. Aspartame acts as a chemical stressor by elevating plasma cortisol levels and causing the production of excess free radicals. High cortisol levels and excess free radicals may increase the brains vulnerability to oxidative stress which may have adverse effects on neurobehavioral health. We reviewed studies linking neurophysiological symptoms to aspartame usage and conclude that aspartame may be responsible for adverse neurobehavioral health outcomes. Aspartame consumption needs to be approached with caution due to the possible effects on neurobehavioral health. Whether aspartame and its metabolites are safe for general consumption is still debatable due to a lack of consistent data. More research evaluating the neurobehavioral effects of aspartame are required.
Asunto(s)
Aspartame/efectos adversos , Enfermedades del Sistema Nervioso/inducido químicamente , Edulcorantes no Nutritivos/efectos adversos , Afecto/efectos de los fármacos , Animales , Aspartame/administración & dosificación , Ácido Aspártico/metabolismo , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Disfunción Cognitiva/inducido químicamente , Disfunción Cognitiva/diagnóstico , Modelos Animales de Enfermedad , Dopamina/metabolismo , Radicales Libres/sangre , Humanos , Hidrocortisona/sangre , Trastornos Migrañosos/inducido químicamente , Trastornos Migrañosos/diagnóstico , Enfermedades del Sistema Nervioso/diagnóstico , Neurotransmisores/antagonistas & inhibidores , Neurotransmisores/metabolismo , Edulcorantes no Nutritivos/administración & dosificación , Norepinefrina/antagonistas & inhibidores , Norepinefrina/metabolismo , Estrés Oxidativo/efectos de los fármacos , Fenilalanina/metabolismo , Convulsiones/inducido químicamente , Convulsiones/diagnóstico , Serotonina/metabolismo , Trastornos del Inicio y del Mantenimiento del Sueño/inducido químicamente , Trastornos del Inicio y del Mantenimiento del Sueño/diagnósticoRESUMEN
OBJECTIVE: d-Allulose, a C-3 epimer of d-fructose, has been reported to decrease body weight and adipose tissue weight in animal studies and is expected to be a potent antiobese sweetener. Our animal study suggested that one of the mechanisms of d-allulose's antiobesity function is an increase in energy expenditure. However, a few studies have thus far explored the underlying mechanism in humans. The aim of this study was to examine the effects of a single ingestion of d-allulose on postprandial energy metabolism in healthy participants. METHODS: Thirteen healthy men and women (mean age of 35.7 ± 2.1 y and body mass index 20.9 ± 0.7 kg/m2) were studied. The study was a randomized, single-blind crossover design with a 1-wk washout period. At 30 min after taking 5 g of d-allulose or 10 mg of aspartame without any sugar as a control, overnight-fasted participants ingested a standardized meal, and energy metabolism was evaluated by a breath-by-breath method. During the experiment, blood was collected and biochemical parameters such as plasma glucose were analyzed. RESULTS: In the d-allulose-treated group, the area under the curve of fat oxidation was significantly higher than in the control group (10.5 ± 0.4 versus 9.6 ± 0.3 kJ·4 h·kg-1 body weight [BW]; P < 0.05), whereas that of carbohydrate oxidation was significantly lower (8.1 ± 0.5 versus 9.2 ± 0.5 kJ·4 h·kg-1 BW; P < 0.05). Furthermore, plasma glucose levels were significantly lower, and free fatty acid levels were significantly higher in the d-allulose group than in the control group. No other parameters such as insulin, total cholesterol, or triacylglycerol were modified. CONCLUSION: d-Allulose enhances postprandial fat oxidation in healthy humans, indicating that it could be a novel sweetener to control and maintain healthy body weight, probably through enhanced energy metabolism.
Asunto(s)
Grasas de la Dieta/metabolismo , Fructosa/administración & dosificación , Periodo Posprandial , Tejido Adiposo/metabolismo , Adulto , Aspartame/administración & dosificación , Glucemia/análisis , Índice de Masa Corporal , Peso Corporal/efectos de los fármacos , Estudios Cruzados , Carbohidratos de la Dieta/metabolismo , Metabolismo Energético/efectos de los fármacos , Ácidos Grasos no Esterificados/sangre , Femenino , Humanos , Insulina/sangre , Masculino , Oxidación-Reducción , Método Simple Ciego , EdulcorantesRESUMEN
Aspartame is a synthetic dipeptide artificial sweetener, frequently used in foods, medications, and beverages, notably carbonated and powdered soft drinks. Since 1981, when aspartame was first approved by the US Food and Drug Administration, researchers have debated both its recommended safe dosage (40 mg/kg/d) and its general safety to organ systems. This review examines papers published between 2000 and 2016 on both the safe dosage and higher-than-recommended dosages and presents a concise synthesis of current trends. Data on the safe aspartame dosage are controversial, and the literature suggests there are potential side effects associated with aspartame consumption. Since aspartame consumption is on the rise, the safety of this sweetener should be revisited. Most of the literature available on the safety of aspartame is included in this review. Safety studies are based primarily on animal models, as data from human studies are limited. The existing animal studies and the limited human studies suggest that aspartame and its metabolites, whether consumed in quantities significantly higher than the recommended safe dosage or within recommended safe levels, may disrupt the oxidant/antioxidant balance, induce oxidative stress, and damage cell membrane integrity, potentially affecting a variety of cells and tissues and causing a deregulation of cellular function, ultimately leading to systemic inflammation.
Asunto(s)
Aspartame/administración & dosificación , Aspartame/toxicidad , Edulcorantes no Nutritivos/administración & dosificación , Edulcorantes no Nutritivos/toxicidad , Animales , Aspartame/farmacocinética , Células Sanguíneas/efectos de los fármacos , Encéfalo/efectos de los fármacos , Bebidas Gaseosas/análisis , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Fibrina/metabolismo , Inocuidad de los Alimentos , Microbioma Gastrointestinal/efectos de los fármacos , Corazón/efectos de los fármacos , Humanos , Sistema Inmunológico/efectos de los fármacos , Riñón/efectos de los fármacos , Hígado/efectos de los fármacos , Estudios Observacionales como AsuntoRESUMEN
A sweetener is a food additive that imparts a sweet taste to food products. Sweeteners have been increasingly used in Korea since the approval of sodium saccharin and d-sorbitol in 1962. Unlike food contaminants, humans are exposed to food additives only through the consumption of processed food products. For exposure assessments of sweeteners, the dietary intakes of food products containing acesulfame-K, aspartame, saccharin-Na, and sucralose were determined, and the resulting calculated estimated daily intake (EDI) values were compared directly with each additive's ADI. The poundage method was used to calculate the daily intake per capita for 12 additional sweeteners, such as lactitol, for which appropriate analytical methods for food products do not exist. The risk, as evaluated by comparing the EDI with the ADI, was determined to be 2.9% for acesulfame-K, 0.8% for aspartame, 3.6% for saccharin-Na, 4.3% for steviol glycosides, and 2.1% for sucralose. No hazardous effect was predicted for the other 11 sweeteners, including lactitol.
Asunto(s)
Dieta , Edulcorantes/administración & dosificación , Edulcorantes/efectos adversos , Aspartame/administración & dosificación , Aspartame/efectos adversos , Aditivos Alimentarios , Humanos , República de Corea , Sacarina/administración & dosificación , Sacarina/efectos adversosRESUMEN
Glucose tolerance and body composition were determined in male rats given non-nutritive sweeteners (NNS) (aspartame or sucralose) in drinking water. Areas under the curve for glucose and insulin with NNS did not differ from control. NNS treatment had no effect on weight gain or percent body fat. Epididymal fat pad mass was higher with aspartame and the ratio of trunk to total fat was less with sucralose versus control, suggesting that NNS consumption altered body fat distribution.
Asunto(s)
Composición Corporal , Prueba de Tolerancia a la Glucosa , Edulcorantes no Nutritivos/administración & dosificación , Adiposidad , Animales , Aspartame/administración & dosificación , Glucemia/metabolismo , Insulina/sangre , Masculino , Edulcorantes no Nutritivos/efectos adversos , Obesidad/sangre , Ratas , Ratas Sprague-Dawley , Sacarosa/administración & dosificación , Sacarosa/análogos & derivados , Aumento de PesoRESUMEN
The consumption of non-nutritive, low, or no-calorie sweeteners (LCS) is increasing globally. Previously thought to be physiologically inert, there is a growing body of evidence that LCS not only provide a sweet taste but may also elicit metabolic effects in the gastrointestinal tract. This review provides a brief overview of the chemical and receptor-binding properties and effects on chemosensation of different LCS but focuses on the extent to which LCS stimulates glucose transport, incretin and insulin secretion, and effects on glucose tolerance. Aspartame and sucralose both bind to a similar region of the sweet receptor. For sucralose, the data are contradictory regarding effects on glucose tolerance in humans and may depend on the food or beverage matrix and the duration of administration, as suggested by longer term rodent studies. For aspartame, there are fewer data. On the other hand, acesulfame-potassium (Ace-K) and saccharin have similar binding characteristics to each other but, while Ace-K may increase incretin secretion and glucose responses in humans, there are no data on saccharin except in rats, which show impaired glucose tolerance after chronic administration. Additional research, particularly of the effects of chronic consumption, is needed to provide concrete evidence for beneficial or detrimental effects of LCS on blood glucose regulation in humans.